Your browser doesn't support javascript.
loading
Pharmacokinetics of meloxicam in pre-ruminant calves after intravenous, oral, and subcutaneous administration.
Jokela, Annemari; Nyrhilä, Alexandra; Adam, Magdy; Salla, Kati; Raekallio, Marja; Aho, Riikka; Norring, Marianna; Hokkanen, Ann-Helena.
Afiliação
  • Jokela A; Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
  • Nyrhilä A; Research Centre for Animal Welfare, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
  • Adam M; Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
  • Salla K; Research Centre for Animal Welfare, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
  • Raekallio M; Research Centre for Animal Welfare, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
  • Aho R; Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
  • Norring M; Pharmacology Department, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef, Egypt.
  • Hokkanen AH; Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
J Vet Pharmacol Ther ; 47(2): 143-149, 2024 Mar.
Article em En | MEDLINE | ID: mdl-37897203
ABSTRACT
Meloxicam is routinely used for pain alleviation in pre-ruminant calves during husbandry procedures. The pharmacokinetics of a single dose (0.5 mg/kg) of meloxicam was investigated after intravenous (IV), subcutaneous (SC), and oral (PO) administration in 30 pre-ruminant calves. Each group included 10 calves. Oral meloxicam was administered at least 1 h after feeding. Plasma samples were collected for up to 168 h, and the meloxicam concentration was analysed with liquid chromatography and mass spectrometry, followed by a noncompartmental pharmacokinetic analysis. The maximum meloxicam concentrations in plasma were 1.91 ± 0.27 µg/mL and 1.77 ± 0.16 µg/mL after SC and PO routes, respectively. The time of maximum concentration was 7.6 ± 2.8 h after SC and 10.0 ± 5.7 h after PO administration. The approximate bioavailability of meloxicam was 97% for SC and PO routes. The elimination half-lives were 79.2 ± 12.4, 84.6 ± 24.8, and 84.8 ± 22.3 h after IV, SC, and PO routes, respectively. The results suggest that the therapeutic meloxicam concentrations in plasma that are required for pain relief in other species, such as horses, may be maintained for several days following a single dose (0.5 mg/kg) administered IV, SC, or PO in calves.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tiazinas / Anti-Inflamatórios não Esteroides Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tiazinas / Anti-Inflamatórios não Esteroides Idioma: En Ano de publicação: 2024 Tipo de documento: Article